Abstract
Purpose :
Previous research looking at optical treatment effectiveness of myopia management interventions in a UK clinic population in a small case series showed 30% of patients on average had successful treatment (Kearney et al., 2022). This study aims to extend this case series, including analysis on myopia management spectacle lenses, to investigate the response to optical myopia management interventions in a UK clinic setting.
Methods :
Data from the myopia management clinic records, Glasgow Caledonian University included age, axial length (AL) and treatment (DIMs, orthokeratology (OK), dual focus (DF) and multifocal (MF) contact lenses)). If data were available, treatment effectiveness was evaluated by three methods: 1. Mean Efficacy Method using the reduction in AL mean values from literature as a target, 2. Emmetropic Growth Method using emmetropic AL growth as a target, 3. Responder/non-responder, a responder demonstrating progression <0.11mm/year.
Results :
A total of 40 patients (80 eyes) were included (DIMs: 42 eyes, DF: 10 eyes, MF: 14 eyes, OK: 12 eyes). At commencement of treatment, mean±stdev SER was -4.29±2.24DS and AL 25.25±1.04. The AL growth rate before treatment (0.28±0.17mm) compares well to control groups. The mean±SD AL growth rate after treatment is 0.17±0.12mm/yr with a mean reduction of 0.12±0.20mm/yr.
Between 30 and 100% of patients had enough data to be evaluated using the various methods. Of these, DIMs showed success in 50% of eyes using the mean efficacy method, 38% success with the emmetropic growth method and 40% were classed as responders, producing a mean±stdev success rate across the 3 measures of 43±6%. The average success across the 3 methods for the other optical interventions was: DF; 26±10%, MF; 36±29%, OK; 22±13%. A total of 68% of eyes were classified as non-responders (progression ≥0.11mm/yr).
Conclusions :
Using currently recommended methods, optical myopia management interventions are successful in a minority of patients in a UK clinic population, including a high number of non-responders compared to clinical trials. The findings support setting realistic expectations and consideration of who to treat in the clinic population, with future research addressing which patients may benefit most from treatment given the low success rates.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.